Drayton joined Insmed in 2014 and has served as SVP, Head of U.S. and General Manager of the ARIKAYCE global program. He became Chief Commercial Officer in May 2022, bringing more than 20 years of pharmaceutical industry leadership experience to the role. During his tenure at Insmed, he has been instrumental in successfully building the U.S. commercial organization, including its capabilities, infrastructure, and team. These efforts contributed to the launch of the Company’s first commercial product in the U.S., ARIKAYCE, which became one of the top 10 most successful non-oncology rare disease launches. Prior to Insmed, Drayton worked for Novartis in positions of increasing responsibility, including National Director, Cystic Fibrosis Sales & Account Management, and Head, Strategy and Operations for the Respiratory Business Unit, a ~$1 billion multi-product specialty business unit. While at Novartis, he contributed to the launch of 14 products across multiple diseases states, and in the role of National Director, his team was responsible for the highly successful launch of TOBI Podhaler. Drayton is passionate about improving patient outcomes, developing culture and talent, building diverse teams to achieve exceptional results, and fostering deep relationships in the KOL and advocacy communities. He is a graduate of The Citadel and holds a Master of Business Administration from Emory University.